Understanding the genetic causes of childhood liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the molecular and genetic basis of pediatric liver cancers, including hepatoblastoma and hepatocellular carcinoma. By collecting biological samples such as tumor tissue, saliva, and blood from affected patients and their families, the study seeks to improve classification systems based on tumor biology rather than just appearance. The goal is to identify genetic defects that could lead to better diagnoses and treatments for these rare cancers. The research will involve both retrospective and prospective data collection to achieve a comprehensive understanding of these conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Prior or current treatment for a childhood liver tumor, malignant or benign, at age \<21 years.
* Biological parents and siblings of eligible children.

Exclusion Criteria:

* No prior or current treatment for a childhood liver tumor.
* Non-biological parents, legal guardians, or non-biological siblings of eligible children.

Where it's running

• UPMC Children's Hospital of Pittsburgh
  Pittsburgh, Pennsylvania, United States Recruiting

Study contacts

• Study coordinator: Morgan Paul, BSN
• Email: Morgan.Paul2@upmc.edu
• Phone: (412) 692-8472

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GPC3-targeted CAR T cells armored with IL-15 and IL-21 for pediatric non‑CNS solid tumors

  This treatment will try personalized CAR T cells that target GPC3 and are engineered to make IL‑15 and IL‑21 in children and young adults with relapsed or refractory non‑CNS solid tumors that express GPC3.

  Recruiting Phase 1 Seattle Children's Hospital · Seattle, Washington · NCT07148050

• IL-15 and IL-21–armored GPC3-CAR T cell therapy for adults with GPC3-positive solid tumors

  This trial tests whether CAR T cells engineered to target GPC3 and fortified with IL-15 and IL-21 can treat adults with GPC3-positive liver and other solid tumors.

  Recruiting Phase 1 Baylor College of Medicine · Houston, Texas · NCT06198296

• InstaSure Non-Invasive Finger-Press Test for HCC

  This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.

  Recruiting Beijing Municipal Administration of Hospitals · Beijing, Beijing Municipality · NCT07848750

• BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

  This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

  Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

• Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer

  This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07793695

• 68Ga-SorB PET/CT imaging for solid tumors

  This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.